News

Filter

Current filters:

Celldex Therapeutics

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

12-06-2014

The glioblastoma multiforme (GBM) treatment market is forecast to expand rapidly from a value of $301…

Celldex TherapeuticsCotaraDCVaxMarkets & MarketingNorthwest BiotherapeuticsOncologyPeregrine PharmaceuticalsPharmaceuticalResearchrindopepimut

Rapid growth forecast for glioblastoma multiforme therapeutics market

Rapid growth forecast for glioblastoma multiforme therapeutics market

06-06-2014

According to a new report, growth in the glioblastoma multiforme (GBM) therapeutics market in major developed…

Celldex TherapeuticsCotaraMarkets & MarketingNorthwest BiotherapeuticsPeregrine PharmaceuticalsPharmaceuticalrindopepimut

Bristol-Myers and Celldex to evaluate nivolumab and varlilumab combo

14-05-2014

US drug major Bristol-Myers Squibb and biotech firm Celldex Therapeutics have entered into a clinical…

BiotechnologyBristol-Myers SquibbCelldex TherapeuticsnivolumabOncologyResearchvarlilumab

Rindopepimut likely to be Rxed by 36% of surveyed US oncologists for GMB patients

05-06-2012

US oncologists surveyed by advisory firm Decision Resources indicate that they would prescribe the emerging…

BiotechnologyCelldex TherapeuticsMarkets & MarketingNorth AmericaOncologyPharmaceuticalrindopepimut

Pfizer returns worldwide rights to Celldex Thera’s rindopepimut brain tumor vaccine candidate

06-09-2010

Massachusetts, USA-based Celldex Therapeutics (Nasdaq: CLDX) saw its stock plummet 36% to $3.05 in pre-market…

Celldex TherapeuticsLicensingOncologyPfizerPharmaceuticalResearchrindopepimut

COMPANY SPOTLIGHT

Menarini

Back to top